The FDA approved Gwyn Lo, a once-weekly combined hormonal contraceptive patch, on July 29, 2026, per Viatris's announcement that day. The patch — norelgestromin with ethinyl estradiol in a low-dose formulation — is worn for three consecutive weeks followed by one patch-free week, and the company expects US availability later in 2026. It is the second new prescription contraceptive product family the agency has approved in 2026. This site publishes information, not medical advice; method choice belongs with you and your own clinician.
What kind of product this is
A contraceptive patch delivers estrogen and progestin through the skin, and it is changed weekly rather than taken daily — the adherence advantage that defines the category. Two patches were already on the US market: Xulane and Twirla. Per Viatris's July 29, 2026 announcement, Gwyn Lo was approved under the 505(b)(2) pathway, supported by the Phase 3 Luminous study, and is formulated as a low-dose option, with lower estrogen exposure than existing patches as the company's stated design goal. Comparative effectiveness and side-effect profiles against the marketed patches will only be known from use and post-approval data, not from the approval itself.
Related stories: Nexplanon now requires REMS certification for every inserter · Title X clinics raced to reapply for funding before the April 1 deadline.
How patches fit among methods
Combined hormonal patches carry the same effectiveness profile as the pill with typical use — about 7 in 100 users become pregnant in a year, per CDC contraception effectiveness guidance, 2024 — because the weekly change is easier to sustain than a daily habit. The patch shares the pill's systemic estrogen exposure, so its contraindications match: a history of blood clots, certain migraine with aura, uncontrolled hypertension, and smoking after age 35 are among the reasons a clinician would steer away from estrogen-containing methods. The progestin-only implant and IUDs remain the most effective reversible options.
What the approval does and does not change
The patch market has been effectively a two-product category for years, so a third entrant adds real option value, particularly if the lower-dose formulation proves easier on estrogen-sensitive side effects such as nausea and breast tenderness — a claim that belongs to Viatris until independent data exist. Pricing and insurance coverage have not been announced; a new brand typically launches at list prices above older patches until formularies negotiate. Patients who do well on an existing patch have no clinical reason to switch.
The context most coverage skipped
The approval lands during a squeezed year for contraceptive access overall: Title X clinics spent spring 2026 reapplying for federal funds under a compressed cycle, and OTC access remains limited to progestin-only pills. In that setting, a new branded prescription patch reaches patients through employer and marketplace coverage that survived 2026 intact — a reminder that method innovation and method access move on separate tracks, and only one of them got good news in July.